Beam TherapeuticsBEAM
About: Beam Therapeutics Inc is a biotechnology company engaged in creating genetic medicines based on its base editing technology. This technology enables a new class of genetic medicines that targets a single base in the genome without making a double-stranded break in the DNA. The company's portfolio comprises Gene Correction, Gene Modification, Gene Activation, Gene Silencing, and Multiplex Editing. The company's pipeline programs consist of BEAM-101, ESCAPE, BEAM-302, BEAM-301, and BEAM-201.
Employees: 374
Fund manager confidence
Based on 2024 Q3 regulatory filings by fund managers ($100M+ AUM)
94% more call options, than puts
Call options by funds: $12.1M | Put options by funds: $6.22M
50% more funds holding in top 10
Funds holding in top 10: 2 [Q2] → 3 (+1) [Q3]
27% more first-time investments, than exits
New positions opened: 28 | Existing positions closed: 22
5% more capital invested
Capital invested by funds: $1.84B [Q2] → $1.93B (+$97.5M) [Q3]
3% more funds holding
Funds holding: 213 [Q2] → 219 (+6) [Q3]
7% more repeat investments, than reductions
Existing positions increased: 72 | Existing positions reduced: 67
0.63% more ownership
Funds ownership: 95.21% [Q2] → 95.84% (+0.63%) [Q3]
Research analyst outlook
4 Wall Street Analysts provided 1 year price targets over the past 3 months
4 analyst ratings
HC Wainwright & Co. Patrick Trucchio 30% 1-year accuracy 47 / 158 met price target | 176%upside $80 | Buy Reiterated | 9 Dec 2024 |
RBC Capital Luca Issi 27% 1-year accuracy 15 / 56 met price target | 17%downside $24 | Sector Perform Maintained | 6 Nov 2024 |
Leerink Partners Rick Bienkowski 29% 1-year accuracy 2 / 7 met price target | 34%upside $39 | Outperform Upgraded | 6 Nov 2024 |
Scotiabank Greg Harrison 33% 1-year accuracy 9 / 27 met price target | 17%downside $24 | Sector Perform Initiated | 16 Oct 2024 |
Financial journalist opinion
Based on 6 articles about BEAM published over the past 30 days